BioCentury
ARTICLE | Finance

Negotiating NASH

Why NEA thinks Metacrine’s FXR agonist could be best in class for NASH

December 8, 2017 11:05 PM UTC

New Enterprise Associates has signed onto Metacrine Inc.’s proposition that there is room to improve upon more advanced FXR agonists in development for non-alcoholic steatohepatitis.

Metacrine closed an untranched $22 million series B round led by new investor NEA on Dec. 6. Existing investors Arch Venture Partners, Polaris, venBio and Alexandria Venture Investments also participated. ...

BCIQ Company Profiles

Metacrine Inc.